COMMUNIQUÉS West-GlobeNewswire

Shape Therapeutics Announces Multiple Oral Presentations at the European Society of Gene & Cell Therapy 32nd Annual Congress
26/09/2025
Talks will cover the use of a novel BBB-penetrant, AAV5-derived CNS capsid and development of an RNA-targeting disease-modifying gene therapy, SHP-201, for treatment of Parkinson’s Disease SEATTLE, Sept. 26, 2025 (GLOBE [...]
Tekton Research Expands Clinical Network with Three New Sites, Five New Investigators, and CNS Thought Leader
26/09/2025
Growth supports Tekton’s strategic focus on CNS and Cardiometabolic research AUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Tekton Research, a leading multi-site clinical trial company, is proud to announce the [...]
Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI
26/09/2025
PALO ALTO, Calif. , Sept. 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non [...]
Glucose Health, Inc. Announces Officer Changes Effective September 30, 2025
26/09/2025
BENTONVILLE, Ark., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) today announced that its Chief Executive Officer and Chief Financial Officer has resigned, effective September 30, 2025, for [...]
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
26/09/2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and [...]
Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities
26/09/2025
ZUG, Switzerland, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the [...]
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
26/09/2025
Carlsbad, CA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients [...]
Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
26/09/2025
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 26 September 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the [...]
ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
26/09/2025
MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, today announced it has been awarded a $2.5 million Phase II [...]
Aveanna to Participate at the Deutsche Bank Annual Leveraged Finance Conference
26/09/2025
ATLANTA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Deutsche Bank Annual Leveraged Finance Conference in [...]
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
26/09/2025
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal BRIDGEWATER, N.J., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or [...]
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
26/09/2025
CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
26/09/2025
CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex [...]
Intelligent Bio Solutions Advances Preparations and Provides Updated Timeline for Anticipated FDA 510(k) Submission and Clearance
26/09/2025
The Company is initiating clinical studies to further validate Intelligent Fingerprinting Drug Screening System INBS anticipates FDA 510(k) clearance in the second half of 2026 NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE [...]
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
26/09/2025
CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of [...]
SS Innovations Appoints Naveen Kumar Amar as Chief Financial Officer
26/09/2025
FORT LAUDERDALE, Fla., Sept. 26, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII) , a developer of innovative surgical robotic technologies dedicated to [...]
Un gala du siècle pour célébrer 100 ans d’espoir, de guérison et d’innovation aux Hôpitaux Shriners pour enfants Canada
26/09/2025
MONTRÉAL, 26 sept. 2025 (GLOBE NEWSWIRE) -- L’Hôpital Shriners pour enfants Canada soulignera son centenaire durant une magnifique soirée-bénéfice, placée sous le signe de la célébration, de la réflexion et de l’ [...]
Shriners Hospitals for Children Canada Hosts Fundraising Gala Celebrating 100 Years of Hope, Healing, and Innovation
26/09/2025
MONTREAL, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Shriners Hospitals for Children Canada is proud to celebrate its centennial with an extraordinary black-tie evening of celebration, reflection, and inspiration. Members of [...]
UPDATE -- ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
26/09/2025
MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, today announced it has been awarded a $2.5 million Phase II [...]

Pages